Published in Br Med Bull on November 07, 2012
Epidemiology of visceral leishmaniasis. Clin Epidemiol (2014) 1.42
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol (2017) 1.38
Genome-wide dissection of the quorum sensing signalling pathway in Trypanosoma brucei. Nature (2013) 1.34
Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends Parasitol (2014) 1.20
A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health (2013) 0.97
Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors. J Med Chem (2014) 0.95
Missing pieces of an ancient puzzle: evolution of the eukaryotic membrane-trafficking system. Cold Spring Harb Perspect Biol (2014) 0.89
A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi. PLoS One (2014) 0.86
Genetic dissection of drug resistance in trypanosomes. Parasitology (2013) 0.86
Determination of antiprotozoal drug mechanisms by metabolomics approaches. Parasitology (2013) 0.86
The double-edged sword in pathogenic trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics. Biomed Res Int (2014) 0.85
Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter. Parasitology (2013) 0.82
The CAF1-NOT complex of trypanosomes. Front Genet (2014) 0.82
Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes. PLoS Negl Trop Dis (2014) 0.82
A comparative analysis of trypanosomatid SNARE proteins. Parasitol Int (2013) 0.81
Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis. Antimicrob Agents Chemother (2015) 0.80
Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery. Int J Parasitol Drugs Drug Resist (2014) 0.80
Arrabidaea chica hexanic extract induces mitochondrion damage and peptidase inhibition on Leishmania spp. Biomed Res Int (2014) 0.80
Resveratrol is active against Leishmania amazonensis: in vitro effect of its association with Amphotericin B. Antimicrob Agents Chemother (2014) 0.79
In Vitro and In Vivo Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives against Leishmania amazonensis. Antimicrob Agents Chemother (2016) 0.79
The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis. Front Immunol (2016) 0.79
Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei. J Med Chem (2015) 0.78
Antitrypanosomal Activities and Mechanisms of Action of Novel Tetracyclic Iridoids from Morinda lucida Benth. Antimicrob Agents Chemother (2016) 0.78
Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms. PLoS Negl Trop Dis (2016) 0.77
Rapid pseudo five-component synthesis of intensively blue luminescent 2,5-di(hetero)arylfurans via a Sonogashira-Glaser cyclization sequence. Beilstein J Org Chem (2014) 0.77
Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors. PLoS Negl Trop Dis (2015) 0.77
Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro. PLoS One (2015) 0.77
Identification of Novel Chemical Scaffolds Inhibiting Trypanothione Synthetase from Pathogenic Trypanosomatids. PLoS Negl Trop Dis (2016) 0.77
Cyclin-Dependent Kinase CRK9, Required for Spliced Leader trans Splicing of Pre-mRNA in Trypanosomes, Functions in a Complex with a New L-Type Cyclin and a Kinetoplastid-Specific Protein. PLoS Pathog (2016) 0.76
Chronic arsenic exposure and microbial drug resistance. Proc Natl Acad Sci U S A (2013) 0.75
Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak. Biomed Res Int (2017) 0.75
Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. Eur J Med Chem (2015) 0.75
Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis. Antimicrob Agents Chemother (2014) 0.75
Targeting the Parasite's DNA with Methyltriazenyl Purine Analogs Is a Safe, Selective, and Efficacious Antitrypanosomal Strategy. Antimicrob Agents Chemother (2015) 0.75
Who Neglects Neglected Tropical Diseases? - Korean Perspective. J Korean Med Sci (2015) 0.75
Metabolomics-Based Study of Logarithmic and Stationary Phases of Promastigotes in Leishmania major by 1H NMR Spectroscopy. Iran Biomed J (2015) 0.75
Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection. Drug Des Devel Ther (2017) 0.75
Pyrimidine Salvage Enzymes Are Essential for De Novo Biosynthesis of Deoxypyrimidine Nucleotides in Trypanosoma brucei. PLoS Pathog (2016) 0.75
Recombinant production, crystallization and crystal structure determination of dihydroorotate dehydrogenase from Leishmania (Viannia) braziliensis. Acta Crystallogr F Struct Biol Commun (2015) 0.75
Unusual Presentation of Cutaneous Leishmaniasis: Ocular Leishmaniasis. Case Rep Infect Dis (2017) 0.75
Killing of Trypanozoon Parasites by the Equine Cathelicidin eCATH1. Antimicrob Agents Chemother (2016) 0.75
The death and life of the resurrection drug. PLoS Negl Trop Dis (2014) 0.75
The Brown Alga Stypopodium zonale (Dictyotaceae): A Potential Source of Anti-Leishmania Drugs. Mar Drugs (2016) 0.75
Multiple chemical scaffolds inhibit a promising Leishmania drug target. IUCrJ (2014) 0.75
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents. Bioorg Med Chem (2016) 0.75
Subverting lysosomal function in Trypanosoma brucei. Microb Cell (2015) 0.75
Ursolic Acid, a Natural Pentacylcic Triterpene from Ochrosia elliptica and Its Role in The Management of Certain Neglected Tropical Diseases. Pharmacogn Mag (2016) 0.75
Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B. Antimicrob Agents Chemother (2017) 0.75
Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate. Open Access Maced J Med Sci (2017) 0.75
Chagas disease. Lancet (2010) 10.25
Cutaneous leishmaniasis. Lancet Infect Dis (2007) 9.32
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 6.94
The trypanosomiases. Lancet (2003) 5.96
Human African trypanosomiasis. Lancet (2009) 5.60
Comparative genomics of trypanosomatid parasitic protozoa. Science (2005) 5.37
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 5.32
Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med (2007) 3.74
Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest (2008) 3.59
Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev (2005) 3.12
Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol (2007) 2.96
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (2011) 2.81
Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med (2010) 2.68
Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet (2000) 2.60
High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature (2012) 2.55
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis (2010) 2.08
Target assessment for antiparasitic drug discovery. Trends Parasitol (2007) 1.96
Leishmaniasis chemotherapy--challenges and opportunities. Clin Microbiol Infect (2011) 1.87
Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg (2010) 1.77
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis (2011) 1.66
Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg (2001) 1.65
Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res (2002) 1.61
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ (1998) 1.60
Recent research on the biological activity of suramin. Pharmacol Rev (1993) 1.60
Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol (2006) 1.56
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
State of the art in African trypanosome drug discovery. Curr Top Med Chem (2011) 1.53
Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev (2009) 1.45
Development of novel drugs for human African trypanosomiasis. Future Microbiol (2011) 1.44
Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs (2010) 1.42
Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.41
A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog (2010) 1.39
The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol Microbiol (2010) 1.39
Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev (2008) 1.35
Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz (2011) 1.26
WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis (2009) 1.16
Update in treatment of Chagas disease. Curr Opin Infect Dis (2011) 1.14
Drug discovery and development for neglected diseases: the DNDi model. Drug Des Devel Ther (2011) 1.05
Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis (2010) 1.02
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis (2009) 1.01
Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis (2011) 0.92
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg Med Chem (2003) 3.21
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Artemisone--a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl (2006) 2.09
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents (2003) 1.83
Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew Chem Int Ed Engl (2004) 1.80
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop (2002) 1.64
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med (2014) 1.57
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother (2006) 1.46
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents (2007) 1.39
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg (2005) 1.36
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother (2010) 1.23
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem (2004) 1.21
Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother (2004) 1.21
Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis (2007) 1.20
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs (2002) 1.17
Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop (2007) 1.16
In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother (2002) 1.14
Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem (2003) 1.12
Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother (2004) 1.12
Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem (2002) 1.11
Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob Agents Chemother (2008) 1.07
Antimalarial compounds from Kniphofia foliosa roots. Phytother Res (2005) 1.00
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother (2003) 0.97
Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J Biol Chem (2004) 0.96
Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferase. PLoS Negl Trop Dis (2013) 0.96
Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic study. Biomed Chromatogr (2008) 0.95
In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem (2004) 0.95
Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg Med Chem (2005) 0.94
Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem (2006) 0.93
Metallocene-based antimalarials: an exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Bioorg Med Chem (2007) 0.93
Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine. Antimicrob Agents Chemother (2010) 0.93
In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica (2009) 0.92
In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani. J Antimicrob Chemother (2011) 0.91
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. J Med Chem (2005) 0.91
Transition metal complexes of buparvaquone as potent new antimalarial agents. 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against Plasmodium falciparum. J Inorg Biochem (2003) 0.90
2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. Bioorg Med Chem (2003) 0.90
Plasmodium falciparum: stage specific effects of a selective inhibitor of lactate dehydrogenase. Exp Parasitol (2005) 0.90
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead. J Med Chem (2003) 0.90
Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J Control Release (2004) 0.89
Antiprotozoal activity of drimane and coloratane sesquiterpenes towards Trypanosoma brucei rhodesiense and Plasmodium falciparum in vitro. Phytother Res (2010) 0.87
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J Med Chem (2004) 0.87
New azasterols against Trypanosoma brucei: role of 24-sterol methyltransferase in inhibitor action. Antimicrob Agents Chemother (2006) 0.87
Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas. Trends Parasitol (2010) 0.86
Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem (2004) 0.86
Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. Curr Opin Infect Dis (2012) 0.86
In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei. Phytother Res (2002) 0.86
Evaluation of azasterols as anti-parasitics. J Med Chem (2006) 0.84
Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. Bioorg Med Chem Lett (2003) 0.83
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur J Med Chem (2009) 0.83
In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J Pharm Pharmacol (2006) 0.83
Antileishmanial activity of two gamma-pyrones from Podolepsis hieracioides (Asteraceae). Acta Trop (2003) 0.83
In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone. Drug Dev Ind Pharm (2010) 0.83
Prediction of anti-plasmodial activity of Artemisia annua extracts: application of 1H NMR spectroscopy and chemometrics. J Pharm Biomed Anal (2004) 0.83
Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase. Mol Biochem Parasitol (2005) 0.82
Assessment of the antiprotozoal activity of Galphimia glauca and the isolation of new nor-secofriedelanes and nor-friedelanes. J Nat Prod (2002) 0.81
Antileishmanial structure-activity relationships of synthetic phospholipids: in vitro and in vivo activities of selected derivatives. Antimicrob Agents Chemother (2007) 0.81
Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid). Mol Pharm (2013) 0.81
Metalloantimalarials: synthesis, X-ray crystal structure of potent antimalarial copper (II) complex of arylazo-4-hydroxy-1,2-naphthoquinone. Bioorg Med Chem Lett (2005) 0.81
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicine. J Nat Prod (2002) 0.81
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid. J Med Chem (2002) 0.80
Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. Bioorg Med Chem (2005) 0.80
Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J Pharm Pharmacol (2007) 0.79
Triclosan is minimally effective in rodent malaria models. Nat Med (2011) 0.79
Cissampeloflavone, a chalcone-flavone dimer from Cissampelos pareira. Phytochemistry (2003) 0.79
Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorg Med Chem (2004) 0.78
Antikinetoplastid activity of 3-aryl-5-thiocyanatomethyl-1,2,4-oxadiazoles. Bioorg Med Chem (2004) 0.78
Developing novel strategies to prevent parasitic infections. Expert Rev Anti Infect Ther (2011) 0.78
Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies. J Pharm Biomed Anal (2006) 0.78
Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex. Antimicrob Agents Chemother (2013) 0.77
Synthesis and in vitro anti-protozoal activity of a series of benzotropolone derivatives incorporating endocyclic hydrazines. Eur J Med Chem (2003) 0.77
Preparation of N-sulfonyl- and N-carbonyl-11-azaartemisinins with greatly enhanced thermal stabilities: in vitro antimalarial activities. ChemMedChem (2007) 0.77
Antimalarial activities of (+)-deoxoartemisitene and its novel C-11, 13 derivatives. Bioorg Med Chem Lett (2004) 0.75
Anti-African trypanocidal and antimalarial activity of natural flavonoids, dibenzoylmethanes and synthetic analogues. J Pharm Pharmacol (2009) 0.75
Neglected diseases: progress in drug development. Curr Opin Investig Drugs (2007) 0.75
In vitro antiprotozoal and cytotoxic activities of some alkaloids, quinones, flavonoids, and coumarins. Planta Med (2004) 0.75